Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients

Sponsor
Ariba Shafiq
Study ID
NCT07367555
Phase
PHASE1
Status
Completed

Conditions

  • Diabete Mellitus

Eligibility Criteria

Sex
ALL
Age
30 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Total of 360 participants were enrolled and prescribed oral 200 mg SGLT-2 tablet. All participants were followed-up for about three months. Body mass index was measured before and after three months and mean change in BMI was assessed.

Key Dates

Start date
Oct 1, 2024
Status verified
Jan 2026
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025

Study Design

Enrollment
360 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Group A participants with Type II Diabetes Mellitus
    Randomly 180 Individuals with diagnosed type 2 Diabetes Mellitus were allocated group A. These individuals were prescribed oral 100 gram Empagliflozin tablet along with diet plan and exercise. All individuals were followed-up in OPD for 3 months. After 3 months, individuals were assessed again for height, weight, and BMI. Changes in weight and BMI were calculated.
  • Active Comparator: Group B participants with Type II Diabetes Mellitus
    Randomly 180 Individuals with diagnosed type 2 Diabetes Mellitus were allocated group A. These individuals were prescribed oral 100 gram Empagliflozin tablet along with diet plan and exercise. All individuals were followed-up in OPD for 3 months. After 3 months, individuals were assessed again for height, weight, and BMI. Changes in weight and BMI were calculated.

Primary Outcome Measure

Weight [ Time Frame: 03 Months ]

Related Studies